35results about How to "Improved benefit/cost ratio" patented technology

The invention belongs to the filed of medicine and discloses a pharmaceutical composition using fimasartan and rosuvastatin or medicinal salt thereof as active components, wherein a mass ratio of rosuvastatin or medicinal salt thereof to fimasartan is 1:0.25-250 and preferably 1:10-100. The pharmaceutical composition containing rosuvastatin medicinal salt thereof and fimasartan has obvious synergism on treating hypertension and complications thereof, low treatment cost, little side-effect and good clinic application prospect.

The invention discloses an oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application and belongs to the field of medicine. The pharmaceutical composition comprises orlistat and lol-suffixed pharmaceutical active ingredients. The usage of orlistat and lol-suffixed pharmaceuticals in the pharmaceutical composition is greatly reduced, thus the risk of pharmaceuticals injuring the human body is reduced. The oral pharmaceutical composition has significant synergistic effect in treating or preventing obesity-related hypertension, can reduce the weight of a patient and the risk of hypertension being complicated by cardiovascular diseases and has higher social value.

The invention discloses an oral medicine composition for treating obesity or vascular hypertension, and belongs to the field of medicine. The medicine composition comprises Orlistat or Cetilista and active ingredients of dipine medicine. In the medicine composition, the use amount of Orlistat or Cetilista and dipine medicine is greatly reduced; particularly, a sustained-release capsule prepared from the medicinal composition can achieve the treatment effect after being taken once a day only, so that the benefit/cost is increased, the patient compliance is improved, and the social value is higher.

The invention relates to a medicament containing theophylines and statins. In the invention, the theophylines and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor form a compound to obtain excellent synergistic effect. The medicament compound greatly reduces the toxic and side effect of aminophylline when used alone, and the pharmacy security is improved.

The invention belongs to the technical field of medicine, and specifically discloses a hypoglycemic drug and its application. It consists of the following raw materials in terms of weight fraction: 5-10 parts of bromocriptine, 15-20 parts of acarbose, and 5-20 parts of kudzu root extract 10 parts, 10-15 parts of xylitol, 0.1-0.5 parts of sorbic acid, 1-5 parts of aspartame, 0.1-0.5 parts of talcum powder and 5-10 parts of dextrin. The hypoglycemic drug of the present invention can effectively solve the problem in the prior art that common hypoglycemic drugs alone cannot effectively control type 2 diabetes, and at the same time have the effects of controlling blood sugar, synergistically protecting endothelial cell function, and reducing diabetic complications.